Current Edition

Quanticate Names David Hukin Senior Director of Pharmacovigilance

London, UK, Quanticate, a leading global data-focused clinical research organisation (CRO) has named David Hukin as the company’s new Senior Director of Pharmacovigilance (PV).

Reporting to Quanticate’s Chief Operating Officer Alan Morgan, Hukin based in the UK will take responsibility for growing Quanticate’s existing PV capabilities.

Hukin has a PhD in Cell Physiology and Biophysics and 15 years’ experience in the pharmaceutical industry, with more than 14 years dedicated to the PV sector.

“Quanticate is an established niche biometric CRO across data services with a well-known reputation of expertise and outstanding quality. I am thrilled to be joining the Quanticate as they accelerate investment in Pharmacovigilance services” said Hukin.

Hukin has worked in small, medium-size and large specialty pharma/biotech companies and has gained pre- and post-marketing experience in a range of therapeutic areas including gastroenterology, hepatology, neurology, oncology and psychiatric conditions as well as advanced therapy medicinal products (ATMPs) and orphan drug indication products for rare diseases.

Alan Morgan added: “Quanticate has experience as a niche biometric CRO and we are always working to further our expertise and service offering through investment and recruitment.”

“The addition of David to the Quanticate team will provide us with the leadership and experience to expand our range of services in PV to better service our client needs.”

“We invested in new technology last year to better scale our PV operations and our clients are already seeing the benefits.”

Quanticate completed an investment initiative to upgrade its Pharmacovigilance safety database and its in-house technology platform in preparation for last years’ Article 2(3) of Directive 2010/84/EU deadline.

This enables Quanticate to offer clients direct and immediate access to a fully compliant safety database without them needing to invest in their own system or use an interim solution to ensure compliance.